Quick answer: NAD+ delivery routes differ mainly in how much of the molecule reaches the bloodstream intact and how quickly it gets there. Intravenous infusion bypasses the digestive tract entirely and places NAD+ directly into circulation, which is why it is the route associated with the flushing, chest tightness and nausea commonly reported when an infusion runs fast. Subcutaneous injection delivers a smaller amount more gradually, and intranasal spray targets absorption across the nasal lining, though human data for that route are sparse. Human research on functional outcomes is still early for every route, so the useful comparison is about absorption and tolerability.
Route of administration is the practical question people arrive at once they start reading about NAD+ for energy, focus and recovery, because the molecule itself is poorly suited to oral use. NAD+ is large and charged, and the digestive tract degrades it before much can be absorbed whole, which moves the conversation toward injections and infusions. What follows compares the routes on absorption, speed and reported tolerability, the terms that actually differ.
Why the route matters at all
Bioavailability is the reason this comparison exists. Taken by mouth, intact NAD+ meets digestive enzymes and the intestinal wall and is largely broken into smaller precursors before reaching circulation. For background on the molecule and why its size and charge create that problem, see what NAD+ is and what it does inside a cell.
Precursors behave differently from NAD+ itself, and keeping them separate clears up most of the confusion in this category. Nicotinamide riboside and nicotinamide mononucleotide are absorbed orally and have raised blood NAD+ markers in human trials, so an oral product is usually a precursor product. Comparing an oral precursor to an NAD+ infusion compares two different interventions.
Speed is the second variable. Faster is not automatically better, since rapid delivery of a metabolically active compound is exactly what tends to produce transient discomfort, and slower routes trade peak levels for comfort.
Intravenous infusion
Intravenous NAD+ places the molecule straight into venous circulation, skipping absorption entirely, which is the strongest argument for the route on pharmacokinetic grounds. Clinics run these infusions slowly over an extended session, and tolerability rather than efficacy is the reason.
Sensations during infusion are consistent enough across accounts to be treated as expected rather than unusual. Flushing, warmth, chest or throat tightness, abdominal cramping, nausea and a feeling of pressure in the head are the ones described most often, and they generally ease when the rate is slowed. Whether they reflect a vasodilatory response, rapid metabolite formation or something else has not been established in published human work.
Session length follows from all of this. Because comfort improves at slower rates, an infusion is a sit-down appointment rather than a quick visit, and that time cost is the main practical tradeoff of the route.
Subcutaneous injection
Subcutaneous administration deposits the compound into the fat layer beneath the skin, where uptake into circulation happens gradually rather than immediately. Slower entry generally means a lower peak concentration and, by most accounts, less of the acute flushing associated with fast infusion, with injection site irritation appearing instead as the more common complaint.
Practicality is the other difference, since subcutaneous administration does not require hours in a clinic chair. Anything self-administered, though, still belongs inside a clinical relationship, with a licensed provider deciding whether the route suits you.
Anything given by injection also raises reasonable questions about sourcing and oversight. A framework for evaluating who is compounding a product and under what supervision is laid out in how to verify a peptide provider before you commit.
Intranasal delivery
Intranasal delivery aims at absorption across the nasal mucosa, a thin and well vascularized surface that avoids first pass metabolism in the liver. Interest in the route comes largely from nose to brain transport along the olfactory and trigeminal pathways, a mechanism demonstrated for some molecules in animal models.
Published pharmacokinetic work on intranasal NAD+ in people, describing how much crosses the nasal lining and where it goes afterward, is sparse, and the nose to brain idea rests largely on animal work with other compounds. Characterizing this route in humans is one of the clearer open questions in the field.
Where the research currently stands
Mechanism and outcome are two different questions, and it is worth being straight about each. The biochemistry of NAD+ is well characterized and not in dispute, and the pharmacokinetics of the delivery routes are reasonably well understood. Human trials testing whether raising NAD+ changes how someone feels or performs are a different matter: most of the encouraging work comes from animal models, the human studies to date are small and short, and this remains an active area of study.
Blood levels are the easy thing to over-read in that context. Showing that a route raises circulating NAD+ or its metabolites answers a pharmacokinetic question rather than a clinical one. How that plays out for energy specifically is covered in how NAD+, mitochondria and age related energy decline actually relate.
Regulatory status belongs alongside it. Compounded preparations are not FDA-approved products, and the distinction between a compounded preparation and an approved drug is one that the difference between research chemicals and prescription therapy covers in more detail.
Frequently Asked Questions
Why does an NAD+ IV cause flushing or chest tightness?
Flushing, warmth and chest or throat tightness are the sensations most commonly reported during intravenous NAD+, and they are usually described as stronger when the infusion runs quickly. Slowing the rate is the standard response clinics describe. The underlying mechanism has not been established in published human work and remains an open question.
Is IV NAD+ better than subcutaneous injection?
Intravenous NAD+ delivers the molecule into circulation immediately and completely, while subcutaneous injection delivers it more gradually at a lower peak. Ranking one above the other implies an outcome comparison that human trials have not yet made. The differences that can be described today are speed, tolerability and the setting each requires.
Does intranasal NAD+ reach the brain?
Nose to brain transport is a real pathway demonstrated for certain molecules in animal studies, and applying it to NAD+ in humans is an extrapolation rather than an established finding. Human data on intranasal NAD+ absorption and distribution are very limited. Studying that route properly in people is still to be done.
Can I just take NAD+ as a capsule instead?
Oral intact NAD+ is poorly absorbed, because the digestive tract degrades the molecule before it enters circulation. Most oral products in this category supply precursors such as nicotinamide riboside or nicotinamide mononucleotide, which are absorbed and have raised blood NAD+ markers in human trials. Choosing an oral product is therefore choosing a precursor strategy.
How long does an NAD+ infusion take?
Infusion sessions are described as lengthy, and the length is driven by tolerability rather than by evidence that a slower rate works better. Running the infusion faster is generally reported to increase flushing and discomfort. Specific rates and durations are clinical decisions made by a licensed provider.
Is any NAD+ delivery route FDA-approved?
Compounded NAD+ preparations are not FDA-approved products and are not equivalent to, or substitutes for, approved drugs. Approval status is separate from whether a preparation is legally compounded by a licensed pharmacy under a valid prescription. Keeping those two ideas distinct is useful when reading anything about this category.
The honest summary
Delivery route determines how much NAD+ reaches circulation and how fast, and on that question the answer is clear: intravenous is immediate and complete, subcutaneous is slower and lower peaking, intranasal is largely uncharacterized in humans, and oral intact NAD+ is poorly absorbed. The mechanism behind all of it is solid; the human outcome research is still early. Choosing between routes is a clinical decision, made with a licensed provider who knows your history, and the tradeoffs worth weighing are absorption, tolerability and oversight.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific reports. 2019. PMID 31278280.
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Advances in nutrition (Bethesda, Md.). 2023. PMID 37619764.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. PMID 36482258.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.